NanoViricides Inc
NNVC - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$33.95M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $33.95 Million |
|---|---|
| Enterprise Value | $-2,794,076,051,750.00 |
| Earnings per Share | $-0.41 |
| Beta | 1.79 |
| Outstanding Shares | 20,188,000 |
Return
| Return on Equity | -22.91% |
|---|---|
| Return on Assets | -20.15% |
| Return on Invested Capital | -23.38% |
Valuation & Multiples
| P/E Ratio | -3.23 |
|---|---|
| PEG | -53.05 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1.38 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 5, 2026
EPS Estimate
$-0.11
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 10.96% |
|---|---|
| Total Invested | $6,084▼ 99.81% |
| Investors Holding | 1▼ 50.00% |
About NanoViricides Inc
12 employees
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus parti...